Complement 3 Glomerulopathy (C3G) Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Complement 3 Glomerulopathy (C3G) Treatment Market Trends and Insights

Approval Of Targeted Complement Therapies And Renal Endpoints

The United States approved iptacopan in March 2025 and pegcetacoplan on July 28, 2025, giving patients with C3G 2 approved disease-specific options. Iptacopan reduced the 24-hour urine protein-to-creatinine ratio by 35.1% relative to placebo at 6 months in APPEAR-C3G^{[1]Novartis, “Novartis Receives Third FDA Approval for Oral Fabhalta Iptacopan, the First and Only Treatment Approved in C3 Glomerulopathy,” Novartis Media Release, novartis.com}. In VALIANT, pegcetacoplan reduced UPCR by 68% at 26 weeks, and 71% of treated patients achieved complete C3c-staining clearance on kidney biopsy. The Complement 3 Glomerulopathy (C3G) treatment market benefits because proteinuria reduction has supported a more practical regulatory pathway for therapies in a very small patient population. The European Commission approved pegcetacoplan in January 2026 for adults and adolescents aged 12 years and older with C3G or primary IC-MPGN. This close timing between U.S. and European access reduces the usual launch gap for rare renal treatments and raises the value of outcome data for the Complement 3 Glomerulopathy (C3G) treatment market.

Expansion Of Diagnostic Testing And Registries

A C3G diagnosis relies on immunofluorescence staining, electron microscopy, and a complement biomarker assessment that can include AP50, CH50, serum C3, sC5b-9, Factor B, Ba, and Bb. Testing can also include C3 nephritic factor, anti-Factor H, and sequencing of complement-related genes, which helps clinicians identify the mechanism involved. KDIGO has called for composite panels that bring functional assays, activation fragments, autoantibodies, and integrated data together rather than depending on one marker. Mayo Clinic Laboratories offers a 15-gene panel that includes C3, CFH, CFHR1-5, CFB, and CFI for relevant complement disorders. Better testing can identify patients whose disease has been missed or classified incorrectly, expanding the diagnosed population available to the Complement 3 Glomerulopathy (C3G) treatment market. European registries also provide a longer record of disease characteristics and care patterns that can help clinicians and payers assess treatment use across countries.

Post-Transplant Care And Tissue-Targeted Approaches

C3G frequently returns after kidney transplantation because the underlying autoantibodies and genetic complement variants can remain after the transplant. In the NOBLE Phase 2 study, post-transplant patients receiving pegcetacoplan had a median UPCR reduction of 54.4% when baseline UPCR was at least 1,000 mg/g. Eighty percent of those patients achieved at least a one-order-of-magnitude reduction in C3c staining, while kidney function remained stable in the study^{[2]Vivarelli et al., “Pegcetacoplan for Posttransplant Patients with Recurrent C3 Glomerulopathy or Primary IC-MPGN,” American Journal of Transplantation, amjtransplant.org}. Native-kidney and post-transplant enrollment in VALIANT supplied randomized evidence across both settings. The Complement 3 Glomerulopathy (C3G) treatment market can therefore reach a separate group of transplant nephrologists managing recurrent disease. Tissue-targeted approaches such as ADX-097 seek to concentrate complement inhibition in affected kidney tissue. They may lower the systemic safety burden for the Complement 3 Glomerulopathy (C3G) treatment market if clinical benefit is established.

Rising Use of Integrated Renal Outcome Endpoints

Regulators approved iptacopan and pegcetacoplan based on proteinuria reduction as a surrogate for long-term kidney survival. In the VALIANT trial, 49% of pegcetacoplan-treated patients achieved eGFR stabilization and a ≥50% reduction in urine protein-to-creatinine ratio (UPCR), compared with 3% on placebo. This composite endpoint is likely to shape Phase 3 trials for next-generation agents and set a competitive benchmark. KDIGO and the ISN emphasize that long-term registry data, including serial biopsy findings, should support short-term surrogate endpoints in real-world treatment decisions. Neither approval requires long-term post-marketing histology data, leaving tissue-level responses in real-world patients unclear. This evidence gap could affect reimbursement decisions in cost-conscious European markets.

Ultra-Rare Population And Fragmented Diagnosis

C3G affects 1-5 individuals per million people each year worldwide, which limits absolute treatment volume even as available therapies expand. Small trials can support approval when endpoints are persuasive, but they leave clinicians and payers with less long-term evidence than they may have for common kidney diseases. A fragmented diagnostic pathway compounds this issue in regions that lack coordinated biopsy, complement testing, and genetic services, slowing access to the Complement 3 Glomerulopathy (C3G) treatment market. Patients may remain on generic immunosuppression when the underlying complement mechanism is not established. The resulting gap is particularly important in developing Asia, South America, and parts of the Middle East and Africa, where specialist access and reimbursement systems remain uneven.

Infection Risk And Long-Term Evidence Gaps

Both approved therapies carry boxed warnings for serious infections caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b. Vaccination is required at least 2 weeks before treatment starts, and clinical teams must coordinate documentation, monitoring, and infection prevention. This requirement can delay treatment initiation in centers without established complement-inhibitor procedures. Current trials also place substantial weight on proteinuria reduction and short-term renal outcomes, while longer-term tissue response remains less certain. The Complement 3 Glomerulopathy (C3G) treatment market will depend on registries and routine-care studies to clarify durability and histologic outcomes. European payers may examine this evidence closely when determining coverage for the Complement 3 Glomerulopathy (C3G) treatment market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Therapy Type: Complement-Targeted Agents Set The Current Standard

Complement-targeted agents held 52.31% of the C3G treatment share in 2025. Their lead reflects the arrival of iptacopan and pegcetacoplan after a period when no approved disease-specific therapy was available. Supportive and renoprotective care remains important, including ACE inhibitors, angiotensin receptor blockers, and SGLT2 inhibitors. Immunosuppressive drugs such as corticosteroids, mycophenolate mofetil, and rituximab are still used because clinicians know these therapies, and they can cost less. Their role is changing because controlled long-term evidence for kidney preservation in C3G remains limited.

Gene and RNA-based therapy is the fastest-growing segment at a 13.58% CAGR from 2026 to 2031. This part of the Complement 3 Glomerulopathy (C3G) treatment industry is being developed around less frequent subcutaneous dosing, including quarterly or twice-yearly schedules. Arrowhead reported 90% mean serum Factor B knockdown after a single 400 mg ARO-CFB dose in its Phase 1/2a study^{[3]Arrowhead Pharmaceuticals, “Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases,” Arrowhead Pharmaceuticals Press Release, arrowheadpharma.com}. SanegeneBio received FDA Orphan Drug Designation in October 2025 for SGB-9768, an RNAi therapy targeting complement C3 mRNA. Plasma therapy and tissue-targeted inhibitors remain smaller categories, but they can support patients who need bridging treatment or have specific autoantibody patterns.

By Disease Subtype: C3GN Leads While DDD Builds Faster

C3 Glomerulonephritis accounted for 66.24% of the Complement 3 Glomerulopathy (C3G) treatment market size in 2025. Its larger presence reflects its stated prevalence among C3G cases and its inclusion in the populations for both approved agents. VALIANT included adults and adolescents aged 12 years and older, which broadened the evidence base across C3GN patients. This segment benefits from more established clinical recognition and a direct link to the current approved treatment pathway. It will remain central to prescribing volume while diagnosis improves.

Dense Deposit Disease is forecast to grow at a 13.22% CAGR from 2026 to 2031. Its more aggressive clinical course can prompt earlier consideration of targeted therapy when clinicians identify its distinct complement profile. DDD is often associated with C3 nephritic factor positivity, dense intramembranous deposits, and earlier progression to end-stage renal disease. The Complement 3 Glomerulopathy (C3G) treatment industry is responding with programs that can address patients whose disease was less visible in earlier trials. Between 10% and 20% of older adults with C3G have an associated monoclonal paraprotein, which can require clone-directed treatment before or alongside complement inhibition. That sequence can delay treatment initiation for a subset of older patients.

By Route Of Administration: Intravenous Care Leads As Oral Treatment Grows

Intravenous administration held 54.64% of the Complement 3 Glomerulopathy (C3G) treatment market size in 2025. This position reflects established intravenous use of cyclophosphamide, rituximab, calcineurin inhibitors, and off-label eculizumab. Intravenous care also remains practical for patients receiving treatment in closely monitored specialist settings. Its lead does not remove the resource demands of infusion capacity, nursing time, and clinic scheduling. Those demands support interest in routes that reduce facility visits.

The oral route is projected to grow at a 12.82% CAGR from 2026 to 2031, supported by iptacopan’s twice-daily regimen. The Complement 3 Glomerulopathy (C3G) treatment market can benefit when oral treatment avoids infusion infrastructure in outpatient nephrology settings. Subcutaneous pegcetacoplan supplies another option because patients can receive treatment at home without a clinic visit. The FDA-approved use model for pegcetacoplan supports patient-administered treatment, including use with an on-body injector. Oral and subcutaneous options still require vaccination records and clinical monitoring, so convenience does not remove safety procedures.

By Distribution Channel: Hospital Pharmacies Retain The Largest Role

Hospital pharmacies accounted for 54.65% of the Complement 3 Glomerulopathy (C3G) treatment market size in 2025. Their role is linked to vaccination logistics, monitoring requirements, and the specialist-led initiation process for complement inhibitors. Academic medical centers and subspecialty nephrology practices diagnose and manage much of the known C3G population. Hospital dispensing can therefore be the first point of access for both approved therapies. This position may be strongest during the early treatment period, when physician supervision is most intensive.

Online pharmacies are forecast to grow at a 12.95% CAGR from 2026 to 2031. Specialty pharmacy networks are adding adherence support, refill systems, home delivery, and services that suit therapies used outside the hospital. Retail pharmacies can also support oral iptacopan in settings where specialty capabilities are available. The Complement 3 Glomerulopathy (C3G) treatment market can shift toward nonhospital channels as maintenance care becomes more routine. European payer rules that require hospital dispensing for biologics and rare-disease products may slow that shift for pegcetacoplan.

Geography Analysis

North America held 42.61% of the Complement 3 Glomerulopathy (C3G) treatment market share in 2025. The United States accounted for most of this regional position because it had the largest diagnosed population, an early reimbursement response, and a high concentration of complement-specialist nephrology programs. Canada and Mexico have patients with C3G, but their specialist networks and diagnostic capacity are smaller. The January 2026 European approval of pegcetacoplan can reduce the usual lead time that U.S. launches have in rare renal diseases.

Europe has an established diagnostic and research structure through the European Reference Network for Rare Kidney Diseases. The CompCure sub-registry had enrolled 350 patients with C3G or IC-MPGN from more than 20 countries by the end of 2025. The broader ERKReg registry includes more than 70,000 patients with rare kidney diseases across 24 European countries and can support local evidence generation, treatment planning, and payer discussions. Access will still vary because national benefit assessments in Germany, France, and the United Kingdom can determine the pace of use.

Asia-Pacific is forecast to grow at a 13.25% CAGR from 2026 to 2031. Expanding specialist nephrology units and regulatory reviews for iptacopan in Japan and China support the region’s position. A survey of Japanese nephrologists reported corticosteroid use in 64% of cases, ACEi or ARB use in 68%, and SGLT2 inhibitor use in 25%. SanegeneBio started a Phase 2 study of SGB-9768 in China in March 2025. The Complement 3 Glomerulopathy (C3G) treatment market will remain limited in the Middle East and Africa and South America by less-developed reimbursement and diagnostic systems. However, GCC countries, Brazil, and Argentina are increasing specialist interest.